Nuvilex Announces Further Enhancement of Patent Position
SILVER SPRING, Md.--(BUSINESS WIRE)--Today, Nuvilex, Inc. (OTCQB:NVLX), through its Singapore-based biotech company associate, SG Austria, announced completion of substantial therapeutic antibody patent portfolio talks, culminating in the addition of the Exclusive Worldwide License to the existing SG Austria patent position for encapsulating therapeutic antibody-producing cells.